<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: One of the earliest signs of vascular change is <z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">endothelial dysfunction</z:e>, which is also known to provoke <z:mp ids='MP_0002871'>albuminuria</z:mp> and to predict cardiovascular prognosis </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of this study was to analyze the effects of renin-angiotensin system (<z:mp ids='MP_0011356'>RAS</z:mp>) blockade on renal endothelial function </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: In a multicenter, prospective, double-blind, forced-titration, randomized study, 96 patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, <z:hpo ids='HP_0000822'>hypertension</z:hpo>, glomerular filtration rate &gt;80 ml/min, and normo- or <z:mp ids='MP_0002959'>microalbuminuria</z:mp> were treated once daily with 40/80 mg <z:chebi fb="0" ids="9434">telmisartan</z:chebi> or 5/10 mg <z:chebi fb="0" ids="8774">ramipril</z:chebi> for 9 weeks </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: The mean +/- SE fall in renal plasma flow (RPF) in response to intravenous N(G)-monomethyl-<z:chebi fb="0" ids="16467,29952">L-arginine</z:chebi> (<z:chebi fb="0" ids="28229">L-NMMA</z:chebi>), reflecting the magnitude of nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> (NO) activity, increased with <z:chebi fb="0" ids="9434">telmisartan</z:chebi> from 71.9 +/- 9.0 ml/min before therapy to 105.2 +/- 9.7 ml/min at the end of treatment (P &lt; 0.001) </plain></SENT>
<SENT sid="4" pm="."><plain>With <z:chebi fb="0" ids="8774">ramipril</z:chebi>, RPF response to <z:chebi fb="0" ids="28229">L-NMMA</z:chebi> increased from 60.1 +/- 12.2 to 87.8 +/- 9.2 ml/min (P = 0.018) </plain></SENT>
<SENT sid="5" pm="."><plain>The adjusted difference between treatments was -17.1 +/- 13.7 ml/min (P = 0.214) </plain></SENT>
<SENT sid="6" pm="."><plain>In accordance, <z:chebi fb="0" ids="9434">telmisartan</z:chebi> increased RPF at rest (i.e., without <z:chebi fb="0" ids="28229">L-NMMA</z:chebi>) from 652.0 +/- 27.0 to 696.1 +/- 31.0 ml/min (P = 0.047), whereas <z:chebi fb="0" ids="8774">ramipril</z:chebi> produced no significant changes in RPF </plain></SENT>
<SENT sid="7" pm="."><plain>The more the basal NO activity improved, the greater was the vasodilatory effect on renal vasculature (r = 0.47, P &lt; 0.001) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: In patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, <z:chebi fb="0" ids="9434">telmisartan</z:chebi> and <z:chebi fb="0" ids="8774">ramipril</z:chebi> both increased NO activity of the renal endothelium significantly, which in turn may support the preservation of cardiovascular and renal function </plain></SENT>
</text></document>